Phenominer Database Results (12 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Clinical Measurement Notes Record ID Study ID
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 111.0 % 3.0 6.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107093 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 48.0 % 14.0 28.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107297 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 385.0 nmol/l 89.0 267.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107305 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 4 0.05 umol/l 0.01 0.02 tissue force analysis utilizing a force transducer 0.0 0 107081 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 0.19 10E-7mol/l 0.05 0.15 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107088 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 0.08 umol/l 0.02 0.05 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107082 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 0.26 10E-7mol/l 0.15 0.3 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107087 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 100.0 % 2.0 6.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107094 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 4 93.0 % 8.0 16.0 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107075 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 59.0 % 4.0 12.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107298 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 407.0 nmol/l 158.0 316.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107304 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 91.0 % 8.0 24.0 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107076 3073